

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/00, 31/135, 31/485, 31/195, 31/557, 31/40</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/27971</b>
			<b>(43) International Publication Date:</b> 2 July 1998 (02.07.98)
<b>(21) International Application Number:</b> PCT/GB97/03525 <b>(22) International Filing Date:</b> 23 December 1997 (23.12.97)  <b>(30) Priority Data:</b> 9626739.8 23 December 1996 (23.12.96) GB 9626750.5 23 December 1996 (23.12.96) GB 9703309.6 18 February 1997 (18.02.97) GB  <b>(71)(72) Applicants and Inventors:</b> KAMM, Michael, Albert [GB/GB]; 4 Willoughby Road, Hampstead, London NW3 1SA (GB). PHILLIPS, Robin, Kenneth, Stewart [GB/GB]; 7 Kewferry Drive, Wormwood, Middlesex HA6 2NJ (GB).  <b>(74) Agent:</b> McMUNN, Watson, P.; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION FOR TREATING FECAL INCONTINENCE AND ANAL ITCH			
<b>(57) Abstract</b> <p>Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an <math>\alpha</math> adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin <math>F_{2\alpha}</math>, dopamine, morphine, <math>\beta</math>-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomosis.</p>			

any mention  
should be against

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITION FOR TREATING FECAL INCONTINENCE AND  
ANAL ITCH

5 This invention relates to the treatment of relief of  
fecal incontinence and anal itch (pruritis ani), particularly  
for patients who have had a major bowel resection and  
reanastomosis.

10 Anal or fecal incontinence is the inability to  
voluntarily control the passage of feces or gas through the  
anus. It may occur either as fecal soiling or as rare  
episodes of incontinence for gas or watery stools. It is a  
very distressing condition that can result in self-inflicted  
social isolation and despair.

15 Conventional treatments for fecal incontinence include  
drug therapy to improve stool consistency, such as morphine,  
loperamide and codeine phosphate to reduce gut motility, and  
laxatives to soften stools and relieve constipation.  
20 Biofeedback training is another treatment which involves  
muscle strengthening exercises to improve anal canal resting  
pressure, and squeeze pressure, and to teach symmetry of anal  
canal function. The most common form of treatment however, is  
surgical repair, such as the creation of a neo-sphincter which  
25 involves grafting on muscle from other parts of the anus, or a  
colostomy. (Gastroenterology in Practice, Summer 1995, p18-  
21; Dig Dis 1990; 8:179-188; and The New England Journal of  
Medicine, April 1992, p1002-1004). In mild cases of anal  
leakage, the patient will often try and plug the anus with a  
30 ball of cotton wall.

In Gut, 1991, 32, p.345-346 it was reported that two  
thirds of patients with idiopathic faecal incontinence had a  
decreased anal resting pressure resulting from an abnormal  
35 internal sphincter function. In many incontinent patients,  
the internal anal sphincter was found to be abnormally thin,  
while others had an external anal sphincter defect.

It has also been reported that *in vitro* contractile response of the internal anal sphincter to noradrenaline is decreased in incontinence, (Br. J. Surg. 1992, vol 79, August, p829-832; Digestive Diseases and Sciences, vol 38, no. 11, Nov. 1993, p1961-1969). A further discussion of the innervation and control of the internal anal sphincter and drugs which can increase or decrease the normal anal resting pressure, is discussed in the text book Coloproctology and the Pelvic Floor (Butterworths), second edition, 1992, at chapter 3 p37-53; Autonomic Control of Internal Anal Sphincter; and Journal of Clinical Investigation 1990, 86: p424-429.

In Surgery 1990; 107: p311-315 sodium valproate was found to be useful in the treatment of minor incontinence after ileoanal anastomosis.

It has now surprisingly been found that fecal incontinence and anal itch can be resolved by treatment with  $\alpha$  adrenergic agonists, nitric oxide synthase inhibitors, prostaglandins  $F_{2\alpha}$ , dopamine, morphine,  $\beta$ -blockers such as propranolol, and 5-Hydroxytryptamine (5-HT).

This is surprising since it was always thought that once an anal sphincter began functioning abnormally, the patient would require major surgery.

In this way the anal leakage is reduced or eliminated without the patient having to undergo major surgery.

Accordingly in a first aspect of the invention there is provided use of a physiologically active agent selected from an  $\alpha$  adrenergic agonist, nitric oxide synthase inhibitor, prostaglandin  $F_{2\alpha}$ , dopamine, morphine,  $\beta$ -blockers, and 5-Hydroxytryptamine in the preparation of a medicament for the treatment or prophylaxis of fecal incontinence or anal itch.

The agents of the invention appear to at least partially treat the incontinence by increasing the resting pressure of the internal anal sphincter.

Preferred agents are  $\alpha_1$  adrenergic agonists, nitric oxide synthase inhibitors, and prostaglandins  $F_{2\alpha}$ .

5        Examples of suitable  $\alpha_1$  adrenergic agonists are nor-adrenalin, methoxamine, but particularly preferred is phenylephrine.

10       Examples of suitable  $F_{2\alpha}$  prostaglandin are dinoprost and carboprost.

15       Examples of suitable NO synthase inhibitors are  $N^G$ -monomethyl-L-arginine (L-NMMA), and  $N^G$ -nitro-L-arginine methyl ester (L-NAME).

20       The medicament can contain a single active agent or a combination of any of the above active agents.

25       Nitric Oxide (NO) synthase inhibitors such as LNMMA have previously been suggested for the therapeutic treatment of septic shock.

30       The prostaglandins, along with thromboxanes and leukotrienes are all derived from 20-carbon polyunsaturated fatty acids and are collectively termed eicosanoids.  $F_{2\alpha}$  prostaglandins are derived *in vivo* from the endoperoxide prostaglandin  $H_2$  which is in turn derived from leukotrienes. Clinically,  $F_{2\alpha}$  prostaglandins such as dinoprost and carboprost are used as uterine stimulants in the termination of pregnancy, missed abortion or the induction of labour.

35       Phenylephrine (an  $\alpha_1$  adrenergic agonist) is used as a mydriatic in ophthalmology, and as a decongestant, for example, in cold and flu remedies.

40       However there has been no suggestion to the inventors knowledge of using any of these active agents to treat fecal incontinence or anal itch.

As used herein "fecal incontinence" includes all types of anal leakage from minor leakage or 'spotting' through moderate leakage, to major instances of faecal incontinence, and  
5 includes neurogenic, active, urge and passive incontinence.

More particularly the class of incontinent patients who will benefit most from the present invention are those with idiopathic incontinence and those whose incontinence is at  
10 least partly due to a weakness of either the internal or external anal sphincter, especially those with a normal or low maximum anal pressure and a structurally intact internal anal sphincter muscle, such as with an abnormally thin sphincter. However patients with minor structural damage such as a  
15 fragmented sphincter would still benefit from the invention. Not only incontinent patients with a damaged or abnormal internal sphincter can be treated, but also patients with a damaged or abnormal external sphincter since the increase in the internal anal resting tone induced by the invention will  
20 compensate for a poorly functioning external sphincter.

Another class of patients who particularly benefit from the invention are post-surgical patients who have had major bowel resection and reanastomosis. For example patients with  
25 ileoanal pouch (restorative proctocolectomy), coloanal (with or without colonic pouch) anastomosis, lower anterior resection, and colectomy with ileorectal anastomosis.

The damage to the sphincter could be caused by trauma,  
30 such as experienced in child birth, surgical operations, or road traffic accidents. Furthermore it is also believed that incontinence caused by primary internal anal degeneration can also be relieved by the invention.

35 Anal leakage also often leads to pruritis of the anus and therefore by reducing or eliminating the leakage, the pruritis or anal itch is also relieved or prevented.

Furthermore, as a result of the increased anal resting pressure, the patient no longer has the discomfort of distended anal sphincter muscles.

5        Physiologically acceptable salts of the above active compounds are also within the scope of the invention. Suitable salts include those formed with both organic and inorganic acids, such as those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic,  
10    pyruvic, acetic, trifluoroacetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic and isethionic acids.

By salt we also mean to include any complex or pseudo  
15    salt wherein the active agent (such as phenylephrine) is associated with, for example, a derivative to an organic or inorganic acid.

Prodrugs and any other bioprecursor which are converted  
20    in vivo to the active agents (such as phenylephrine) are also within the scope of the invention.

A particularly preferred salt of phenylephrine is the hydrochloride salt.

25

Although the medicament can be administered, for example, orally or intravenously to systemically treat the faecal incontinence, it is preferred that the incontinence is treated by local or topical application of the medicament in and/or  
30    around the anal canal of the incontinent patient.

Alternatively the agents of the invention can be locally injected directly into the internal anal sphincter. In both locally and systemically acting compositions, at least a pharmacologically acceptable carrier will be present along  
35    with the active.

Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as

capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; oil-in-water liquid emulsions or water-in-oil liquid emulsions.

5

Pharmaceutical composition adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water, immediately prior to use.

Pharmaceutical compositions adapted for topical administration in and/or around the anal canal may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, foam, oils, suppositories or enemas.

The topical compositions can comprise emulsifiers, preservatives, buffering agents and anti-oxidants. Preferably the compositions also comprise steroids and locally acting anaesthetics.

The dosage of the composition will depend on the severity of the incontinence, the route of administration, the age, weight and condition of the patient being treated. For example a suitable daily dosage of medicament, such as phenylephrine, based on a 70kg patient with moderate faecal incontinence would be 40 mg/day to 2000 mg/day, such as 40 to 400 mg or 40 to 200 mg/day, preferably at a lower limit of at least 50 mg/day.



For rectally administered topical compositions such as phenylephrine, the percentage of active is preferably at least 5% w/w, more preferably at least 10% w/w, and advantageously up to about 50% w/w of the composition. The dosage of active  
5 such as phenylephrine is preferably at least 40mg per 0.5ml of composition, more preferably at least 50mg per 0.5ml of composition, such as up to about 250mg/0.5ml. In fact, early investigations indicate that higher dosages will be more beneficial because of the subnormal sensitivity of the anal  
10 sphincter. The total amount of active present in a topical composition (such as a tube) is suitably from 40 to 5000mg, such as 40mg to 1000mg, or 40 to 500mg of active. The topical composition should be applied 1 to 6 times daily, such as 3 times daily until there is a relief from the incontinence.

15

The topical composition may comprise skin penetrating agents, particularly the sulfoxides, such as dimethyl sulfoxide (DMSO) preferably at 25% to 50% w/w. Amides, (DMA, DMF) pyrrolidones, organic solvents, laurocaprom  
20 (AZONE) and calcium thioglycollate are suitable alternative penetrants. The composition may also optionally contains a polyacrylic acid derivative, more particularly a carbomer. This would both act as a skin hydrating agent to aid penetration of the drug, but also an emulsifying agent.  
25 The carbomer will help emulsify the DMSO, thereby mitigating skin irritation and providing enhanced skin hydration. Propylene glycol may also be present in the composition to soften the skin, increase thermodynamic potential and aid skin penetration by the DMSO and thus the  
30 drug. The final pH of the composition is advantageously pH 3.5 to 4.5.

Yet further aspects of the invention provide:

- 35 (1) a method for the treatment of fecal incontinence or anal itch comprising administering to the patient, a therapeutically active amount of an agent serving to increase the internal anal sphincter pressure; and

(2) a method for the treatment of fecal incontinence or anal  
itch comprising administering to the patient, preferably  
by local application to the internal anal sphincter, a  
5 pharmacologically active agent selected from an  $\alpha_1$   
adrenergic blocker, nitric oxide synthase inhibitor,  
prostaglandin  $F_{2\alpha}$ , dopamine, morphine,  $\beta$ -blockers, and 5-  
Hydroxytryptamine.

10 The invention will now be described by way of example  
only with reference to the accompanying drawings in which:

Figure 1 represents a graph of maximum anal resting  
pressure after 0.5ml of 10% phenylephrine (50mg) applied  
15 intraanally in healthy volunteers;

Figure 2 represents a dose dependent graph of  
phenylephrine in healthy volunteers (preRx = Pre-treatment;  
MRP +/- 1SD);

20

Figure 3 represents a graph of maximum anal pressure in  
healthy volunteers before and after application of 10%  
phenylephrine;

25 Figure 4 represents a graph of the duration of action of  
10% phenylephrine; and

Figure 5 represents a graph of maximum resting anal  
pressure after 0.5ml of 10% phenylephrine (50mg) applied  
30 intraanally in 10 patients with passive faecal incontinence.

#### Example 1:

#### Protocol

35

Preparations of commercially available ophthalmic 10%  
phenylephrine hydrochloride (Minims) solution were  
administered intraanally with the subject in the left lateral

position. The doses are expressed as both a volume of a concentration of phenylephrine solution and also as milligrams of phenylephrine. Before using ophthalmic phenylephrine solution intraanally, ointment preparations of phenylephrine made up in yellow soft paraffin were applied to the anal margin, but it was found this had no effect up to a dose of approximately 500mg 10% ointment (50 mg of phenylephrine). This probably represents failure of transcutaneous absorption and thereafter only ophthalmic phenylephrine solution was instilled intraanally.

Manometry (to determine the maximum resting anal pressure) was performed using a water-filled microballoon system connected to a plastic rigid catheter and transducer and then to a pen chart recorder. Maximum resting anal pressure was obtained using a station pull through technique. The catheter was taped to the buttock and a continuous reading performed until a steady anal pressure was achieved. After the drug was administered, continuous pressure readings were taken for between 15 and 31 minutes. Pulse rate and blood pressure were monitored and the subject questioned for headache, anxiety, palpitations and abdominal or anal pain.

#### Dose response study in single volunteer

Ten percent phenylephrine was serially diluted with 0.9% saline and a standard 0.5 ml dose given to a single healthy volunteer. Commencing at 1%, increasing concentrations of phenylephrine were administered on different days until there was a rise in the resting anal pressure. To assess duration of action, in this one volunteer only, manometry was repeated at 13 hours.

There was no significant increase in the maximum resting pressure with 0.5 ml 0.1% (0.5 mg), 0.5% (2.5 mg), 1% (5 mg) or 5% (25 mg) phenylephrine. When 0.5 ml 10% phenylephrine (50 mg) was instilled into the anal canal, there was an increase in the resting pressure from 120 to 210 cm H<sub>2</sub>O (12-21

KPa). The increase in resting anal pressure was evident throughout 25 minutes of continuous recording but returned to pre-treatment level 13 hours later.

5 Example 2:

Healthy volunteer group

Ten healthy volunteers (five men) received an intraanal  
10 dose of the 0.5 ml 10% phenylephrine (50 mg) according to  
example 1. Median age was 26 years (range 22-37). None of  
the volunteers had symptoms of anal incontinence nor previous  
anal surgery and all the women were nulliparous and therefore  
presumed to have intact internal and external anal sphincters.  
15 Pre-phenylephrine median resting pressure was 110 cm H<sub>2</sub>O (11  
KPa) (range 45-125 cm H<sub>2</sub>O ; 4.5-12.5 KPa).

After the application of 0.5 ml 10% phenylephrine (50  
mg), there was a significant increase in the maximum resting  
20 pressure to 180 cm H<sub>2</sub>O (17.5 KPa) (range 120-210 cm H<sub>2</sub>O; 12-  
20.5 KPa) (p<0.05, Wilcoxon sign rank test) (Figure 1). The  
increased pressure was maintained for the duration of the  
recording, a median of 23 minutes (range 14-31 minutes).

25 Example 3:

A composition of base gel had the following composition:  
carmellose sodium 6g, polyethylene glycol 30ml,  
methylhydroxybenzoate 150mg, propylhydroxybenzoate 15mg, made  
30 up to volume with distilled water (pH4).

Various amounts of phenylephrine was added at 5%, 10%,  
20% and 30% w/w to form various compositions for dose ranging  
studies (Figure 2).

Example 4:

5 A base cream of the invention had the following composition:

Dimethyl sulphoxide	250g
Carbomer 974P	5g
White soft paraffin	15g
Cetomacrogel emulsifying ointment*	115g
Propylene glycol	23g
Methylhydroxybenzoate (preservative soln)	to volume

to which 10% w/w phenylephrine hydrochloride was added.

- 10 \*composition: white soft paraffin 50g, liquid paraffin 20g, cetomacrogel emulsifying wax 30g (cetosteryl alcohol 24g and cetomacrogel 1000, 6g).

15 A base cream was formed by firstly separate mixing of the aqueous and non-aqueous components of the cream. Weighed quantities of propylene glycol and a proportion of the preservative solution were placed in a beaker to which the weight quantity of carbomer powder was added using an impeller type mixer to form a colloidal suspension of the carbomer.

20 Thereafter, the weighed quantity of DMSO was added and rapid stirring continued at room temperature until a translucent uniform gel had been formed.

25 In the meantime, the weighed quantities of white soft paraffin and the cetamacrogel emulsifying ointment were placed in a separate beaker, heated to melting point and gently stirred to give a uniform base.

30 The drug is then added to the remainder of the preservative solution, which in turn was then added to the gel and whilst vigorously stirring, the uniform base (above) was added to form a cream. The carbomer acting as a dual

neutralisation agent and primary emulsifier (of the oil and aqueous phases) to form the uniform cream base.

Example 5:

5

Twelve human volunteers aged 21 to 53 (mean 35) were studied on 4 occasions. Measurements of resting anal sphincter pressure and anodermal blood flow (using a laser doppler flowmeter) were taken before and after topical application of increasing concentrations of phenylephrine gel according to example 3 (supplied by Slaco Pharma (UK) Ltd) to the anus. Readings were taken through the day after a single application in order to determine the duration of effect.

15 As can be seen from Figure 2, there was a dose dependent increase in the mean resting anal sphincter pressure (MRP) with a small (6%) rise after 5% phenylephrine ( $p = 0.04$ ) and a clinically significant 33% rise with 10% phenylephrine compared to the pre-treatment sphincter pressure ( $85 \pm 12$  v 20  $127 \pm 12$  cmH<sub>2</sub>O pre v post treatment MRP.  $P < 0.0001$ ) - Figure 3. Thereafter no additional response was noted with higher concentrations of phenylephrine. Duration of action of a single application of 10% phenylephrine was a median of 7 (range 6 to 8) hours (Figure 4). No notable changes were 25 recorded in the anodermal blood flow. Therefore topical application of 10% phenylephrine gel significantly increases the resting anal sphincter pressure in healthy volunteers.

Example 6:

30

Patient group

Ten patients (3 men) also received an intraanal dose of 0.5 ml 10% phenylephrine (50 mg) according to example 1. 35 Their median age was 45 years (range 27-76). All had passive incontinence with or without urge faecal incontinence. Patients were selected on the basis of having passive faecal incontinence which is known to be associated with internal

sphincter damage. To determine if the treatment is useful in those with structural fragmentation or simply thinning of the internal anal sphincter, five of each type of patient were collected.

5

Pre-phenylephrine median resting pressure was 25 cm H<sub>2</sub>O (2.5 KPa) (range 20-100 cm H<sub>2</sub>O; 1-10 KPa). Endoanal ultrasound demonstrated an abnormal internal anal sphincter in all patients. In half the patients it was structurally  
10 fragmented while in the other five patients it was intact but abnormally thin (less than 1 mm). Seven patients also had some structural damage to the external anal sphincter, while in three it was circumferentially intact.

15

After intraanal instillation of 0.5 ml 10% phenylephrine (50 mg) the median maximum resting pressure rose to 55 cm H<sub>2</sub>O (5.5 KPa) (range 20-80 cm H<sub>2</sub>O; 2-8 KPa) (p=0.39, Wilcoxon sign rank test) (Figure 5). Seven patients demonstrated a rise in anal pressure while two showed a fall and one patient showed  
20 no change. Increased resting pressure was seen in patients with both a fragmented, and a structurally intact, but thin, internal sphincter. The pre-treatment resting pressure did not predict the response to phenylephrine.

25

The pressure rise in incontinent patients although less consistent and not as marked as in healthy patients, is nevertheless surprising and therapeutically valuable in treating incontinence. The lower increase in resting anal pressure of incontinent patients can be explained in view of  
30 the known pathology of this condition. Patients with passive faecal incontinence have increased fibrosis and collagen replacement of the internal anal sphincter. Therefore although the absolute rise in resting anal pressure from phenylephrine was not as marked in responding patients  
35 compared with controls, it is nevertheless a major advance in the non-surgical treatment of passive faecal incontinence.

Although some patients did not respond to phenylephrine, this may be due to a structural abnormality or to an altered sensitivity of their internal anal sphincter. These patients will probably require an increased dose (over the 50mg tested  
5 in this study) to produce a rise in their resting anal pressure.

Example 7:

10 A prospective randomised placebo controlled cross over trial was undertaken to evaluate the use of 10% phenylephrine topical cream (according to examples 3 and 4) for treatment of idiopathic passive fecal incontinence.

15 30 Patients completed the study. All patients were assessed by endoanal ultrasound as well as anorectal physiology (to determine maximum resting anal pressure) and laser doppler flowmetry prior to treatment. The latter two measurements are repeated after a 3 week trial of the active  
20 agent (phenylephrine 10%) and placebo 'Incontinence scores' are determined before and after each treatment.

Of the 30 patients studied, three (10%) had significant subjective improvements of their symptoms after phenylephrine compared to the pre-treatment baseline, and to placebo. All  
25 three were women, aged 55 to 64 (mean 59), who had low/normal resting sphincter pressure prior to treatment and structurally intact anal sphincter on ultrasound. Anorectal manometry showed no significant change in mean resting pressure after  
30 10% phenylephrine (from 62 to 58 cmH<sub>2</sub>O, pre and post phenylephrine). Similarly no significant change in pressure was noted after placebo. Incontinence score improved from mean of 14 to mean of 10. There was no significant change in anodermal blood flow after phenylephrine or placebo.

35

In summary 3/30 patients with idiopathic fecal incontinence had subjective improvement of their symptoms



after topical application of 10% phenylephrine cream, with noticeable improvement in their incontinence score.

Example 8:

5

A prospective randomised placebo controlled cross over trial was undertaken to evaluate the use of phenylephrine 10% topical cream (according to examples 2a and 3) for treatment of fecal incontinence in patients with ileo-anal pouch.

10

12 Patients were enrolled in the study of whom 10 have completed the study. 10 Patients are mainly troubled by nocturnal incontinence only, and 2 have both daytime and nocturnal incontinence.

15

Of the 10 completed studies, there were 7 women and 3 men, age range (34-67). Anorectal manometry was performed and laser doppler fowmetry on all patients. Incontinence score was determined. All these outcome measures were repeated after treatment with both trial creams (phenylephrine and placebo).

20

6/10 (60%) patients had significant improvement of their symptoms with phenylephrine 10% compared to placebo. This correlated well with the rise in mean resting anal sphincter pressure in these patients after phenylephrine but not after placebo (29% increased after phenylephrine, v-8% on placebo compared to baseline,  $p < 0.005$ ). Incontinence scores improved by a mean of 45% after phenylephrine compared to 3% after placebo. No differences in anodermal blood flow were noted. The mean subjective improvement in symptoms reported by patients was 83% after placebo and 14% after placebo ( $p < 0.01$ ).

30

One patient had no measurable increase in anal sphincter pressure, though her incontinence score improved by 47% and subjectively she felt 75% better after phenylephrine compared to placebo. 3/10 patients had no improvement.

35

In summary, 7/10 patients with ileo-anal pouch had improvement of symptoms of incontinence after topical application of 10% phenylephrine cream, 6 of whom also had objective improvement i.e. measurement of anal sphincter pressure.

Example 9:

A 1% ointment was prepared by mixing 0.02g of N $\omega$ -Nitro-L-arginine (obtained from Fluka - part of the Sigma group) in 19.8g of unguentum merk base.

The ointment was then applied in and around the anal canal of twelve patients and the internal anal pressure measured by manometry (as discussed previously) before and shortly after application of the ointment. The patients suffered from passive and urge (P+U) incontinence, or constipation, and ultra-sound showed most patients to have an internal anal sphincter (IAS) and external anal sphincter (EAS) defect.

The results are given in Table 1 and show that nitric oxide synthase inhibitors such as N $\omega$ -Nitro-L-arginine increase the resting internal anal sphincter pressure and relieve anal incontinence and anal itch.

TABLE 1

	Patient age/sex	Diagnosis	Anal Ultra-sound	Internal Anal Pressure/Pre Application	Post Application
1	24 M	P+U Incont.	IAS & EAS Defect	80	100
2	81 M	P+U Incont.	IAS & EAS Defect	40	50
3	97 M	P+U Incont.	IAS & EAS Intact	80	100
4	24 F	Constipation		80	100
5	37 F	Constipation		80	100
6	38 F	Constipation		60	80
7	37 M	P+U Incont.	s/p Sphinctorectomy IAS & EAS Defect	40	50
8	37 F	Constipation	IAS & EAS intact	80	100
9	73 M	P+U Incont.	IAS & EAS Intact	60	60
10	55 F	P+U Incont.	IAS & EAS Intact	40	60
11	60 F	P+U Incont.	IAS & EAS Defect	30	40
12	M	P+U Incont. Viserol Myopathy	IAS & EAS Intact	30	30

CLAIMS

1. Use of a physiologically active agent selected from an  $\alpha$  adrenergic agonist, nitric oxide synthase inhibitor,  
5 prostaglandin  $F_{2\alpha}$ , dopamine, morphine,  $\beta$ -blockers, and 5-Hydroxytryptamine in the preparation of a medicament for the treatment or prophylaxis of fecal incontinence or anal itch.
- 10 2. Use as claimed in Claim 1 wherein the active is selected from an  $\alpha_1$  adrenergic agonist, a nitric oxide (NO) synthase inhibitor, and a  $F_{2\alpha}$  prostaglandin.
- 15 3. Use as claimed in Claim 2 wherein the  $\alpha_1$  adrenergic agonist is phenylephrine, nor-adrenalin or methoxamine, the  $F_{2\alpha}$  prostaglandin is dinoprost or carboprost, and the NO synthase inhibitor is  $N^G$ -monomethyl-L-arginine (L-NMMA), and  $N^G$ -nitro-L-arginine methyl ester (L-NAME), and pharmacologically acceptable salts of all of the above.
- 20 4. Use as claimed in Claim 3 wherein the  $\alpha_1$  adrenergic agonist is phenylephrine and pharmacologically acceptable salts thereof.
- 25 5. Use as claimed in any one of the preceding claims wherein the medicament is for local application to the internal anal sphincter.
- 30 6. Use as claimed in Claim 5 wherein the topical medicament is for topical application and is a gel, ointment, cream, emollient, lotion, powder, solution, suspension, spray, paste, oil, foam, suppository, or enema.
- 35 7. Use as claimed in any one of the preceding claims wherein the patients to be treated have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle.

8. Use as claimed in any one of Claims 1 to 6 wherein the patients to be treated have had major bowel resection and reanastomosis.
- 5 9. A rectally administrable topically acting pharmaceutical composition for local application in the treatment of fecal incontinence or anal itch comprising at least one active selected from an  $\alpha$  adrenergic agonist, a NO synthase inhibitor, and a  $F_{2\alpha}$  prostaglandin, dopamine, morphine,  $\beta$ -blocker and 5-HT together with a pharmacologically acceptable carrier.
- 10 10. A topical composition as claimed in Claim 9 wherein the active is as further defined in Claims 2 to 4.
- 15 11. A topical application wherein the active is phenylephrine at, at least 10%.
- 20 12. A composition as claimed in any one of Claims 9 to 13 in the form of a gel, ointment, cream, emollient, lotion, powder, solution, spray, paste, oil, suspension, enema, foam or suppository.

1/4




FIGURE 1

2/4




FIGURE 2

3/4




FIGURE 3

10% phenylephrine: duration of action




FIGURE 4



4/4




FIGURE 5

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/03525

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/135 A61K31/485 A61K31/195 A61K31/557  
A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	P.ENCK ET AL.: "Die Behandlung der Analinkontinenz" INTERNIST, vol. 34, no. 1, 1993, pages 51-58, XP002059672	1-3
Y	see page 53 - page 54; table 2 ---	5-12
X	DAVID E. BURLEIGH ET AL: "Neural and pharmacologic factors affecting motility of the internal anal sphincter" GASTROENTEROLOGY, vol. 84, no. 2, 1983, pages 409-417, XP002059673	1-3
Y	see page 411, right-hand column - page 413, left-hand column --- -/--	5-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

20 March 1998

Date of mailing of the international search report

09. 04. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tzschoppe, D

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/03525

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHIGERU YAMATO ET AL.: "Role of alpha adrenoceptors in opossum internal anal sphincter" J.CLIN.INVEST., vol. 86, no. 2, 1990, pages 424-429, XP002059674	1-4
Y	see abstract see page 424, left-hand column	5-12
X	HERBERT B. HECHTMANN ET AL.: "Moderation of anal sphincter tone with nitric oxide agonists and antagonists" ARCHIVES OF SURGERY, vol. 131, no. 7, 1996, pages 775-778, XP002059675	1-3
Y	see page 775	5-12
X	SATISH RATTAN ET AL.: "Role of nitric oxide as a mediator of internal anal sphincter relaxation" AM.J.PHYSIOL., vol. 262, no. 1pt1, 1992, pages 107-112, XP002059676	1-3
Y	see abstract	5-12
X	WO 91 00730 A (DAK-LABORATORIET A/S) 24 January 1991	9,10,12
Y	see page 15, paragraph 3 see page 10, line 14	11
X	US 5 436 009 A (TJOE H. JAUW ET AL.) 25 July 1995 see example II	9,10,12
X	US 5 213 808 A (D.BAR-SHALOM ET AL) 25 May 1993 see column 4, line 33 - line 39 see column 7 - column 9	9,10,12
X	US 4 292 300 A (GOEFFREY A. BYRNE ET AL) 29 September 1981 see abstract	9,10,12
Y	see claim 6	11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/03525

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9100730 A	24-01-1991	AT 107858 T	15-07-1994
		AU 638992 B	15-07-1993
		AU 5630890 A	06-02-1991
		CA 2063598 A,C	08-01-1991
		DE 69010336 D	04-08-1994
		DE 69010336 T	03-11-1994
		EP 0480934 A	22-04-1992
		ES 2055911 T	01-09-1994
		JP 2584899 B	26-02-1997
		JP 4507091 T	10-12-1992
		LT 702 A,B	31-01-1995
		LV 10192 A,B	20-10-1994
		US 5422352 A	06-06-1995
US 5436009 A	25-07-1995	CA 2099557 A	03-01-1995
		NL 9102142 A	16-07-1993
		AT 137956 T	15-06-1996
		DE 69210787 D	20-06-1996
		EP 0550100 A	07-07-1993
		ES 2090490 T	16-10-1996
		JP 5245187 A	24-09-1993
		DE 69210787 T	02-01-1997
US 5213808 A	25-05-1993	AT 106719 T	15-06-1994
		AU 6505190 A	18-04-1991
		DE 69009769 D	14-07-1994
		DE 69009769 T	22-12-1994
		WO 9104015 A	04-04-1991
		EP 0493513 A	08-07-1992
		JP 5500668 T	12-02-1993
US 4292300 A	29-09-1981	GB 1593261 A	15-07-1981
		US 4265875 A	05-05-1981
		US 4406883 A	27-09-1983

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**